Background: Renal disease is associated with ineffective erythropoiesis. In such patient populations, reports on the extent, complications, and management of iatrogenic iron overload (IO), following repeated blood transfusions and intravenous iron supplementation, are rare. Patients and Methods: Over the past 5 years, 3572 patients on different modalities of renal therapies, viz. conservative, maintenance hemodialysis, maintenance peritoneal dialysis, and kidney transplantation, were screened for IO and its subsequent liver, endocrine, and heart complications. Diagnosis of IO was established by high transferrin saturation %, serum ferritin, bone marrow stores, and CT density. Liver disease was suspected with abnormal liver tests and abdominopelvic sonography. After exclusion of other causes of liver diseases, a liver biopsy was done to assess for IO-hepatopathy. In those patients, basal and dynamic hormonal tests as well as echocardiography were used to assess for IO-endocrinopathy and IO-cardiopathy. Results: A total of 823 (23%) had IO, of whom 23 patients with severe and long-standing exposure had IO-hepatopathy (6 with severe hemosiderosis and 17 with cirrhosis). In those patients, 2 had pituitary disease and 2 had dilated cardiomyopathy. Weekly phlebotomy for 1 month followed by twice monthly phlebotomy normalized their iron balance by 3 months in all patients with IO and halted the liver, endocrine, and heart complications, in the affected ones, by 42 ± 11 months of follow-up. Conclusion: IO-hepatopathy, endocrinopathy, and cardiomyopathy can develop following inappropriate and excessive intravenous iron infusions in renal patients on different RRT. Vigilant monitoring of their hematinic therapy is indicated and therapeutic phlebotomy is useful in its management.
References
[1]
Tian, Y., Tian, Y., Yuan, Z., Zeng, Y., Wang, S., Fan, X., et al. (2022) Iron Metabolism in Aging and Age-Related Diseases. InternationalJournalofMolecularSciences, 23, Article 3612. https://doi.org/10.3390/ijms23073612
[2]
Madiwale, T. and Liebelt, E. (2006) Iron: Not a Benign Therapeutic Drug. CurrentOpinioninPediatrics, 18, 174-179. https://doi.org/10.1097/01.mop.0000193275.62366.98
[3]
Powell, L.W., Nathan Subramaniam, V. and Yapp, T.R. (2000) Haemochromatosis in the New Millenium. JournalofHepatology, 32, 48-62. https://doi.org/10.1016/s0168-8278(00)80415-8
[4]
Baddam, S. and Chen, R.J. (2025) Iron Overload and Toxicity. StatPearls.
[5]
Canavesi, E., Alfieri, C., Pelusi, S. and Valenti, L. (2012) Hepcidin and HFE Protein: Iron Metabolism as a Target for the Anemia of Chronic Kidney Disease. WorldJournalofNephrology, 1, 166. https://doi.org/10.5527/wjn.v1.i6.166
[6]
Richardson, K.J., McNamee, A.P. and Simmonds, M.J. (2018) Haemochromatosis: Pathophysiology and the Red Blood Cell1. ClinicalHemorheologyandMicrocirculation, 69, 295-304. https://doi.org/10.3233/ch-189128
[7]
Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. and Adamson, J.W. (1987) Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin. Results of a Combined Phase I and II Clinical Trial. NewEnglandJournalofMedicine, 316, 73-78. https://doi.org/10.1056/nejm198701083160203
[8]
Kuji, T., Toya, Y., Fujikawa, T., Kakimoto-Shino, M., Nishihara, M., et al. (2015) Acceleration of Iron Utilization after Intravenous Iron Administration during Activated Erythropoiesis in Hemodialysis Patients: A Randomized Study. Therapeutic Apheresis Dialysis, 19, 131-137. https://doi.org/10.1111/1744-9987.12237
[9]
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., et al. (2004) IL-6 Mediates Hypoferremia of Inflammation by Inducing the Synthesis of the Iron Regulatory Hormone Hepcidin. JournalofClinicalInvestigation, 113, 1271-1276. https://doi.org/10.1172/jci200420945
[10]
Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., et al. (2004) Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science, 306, 2090-2093. https://doi.org/10.1126/science.1104742
[11]
Nashwan, A.J., Abuawwad, M.T., Jaradat, J.H., Ibraheem, A., Yassin, M.A. and Taha, M.J.J. (2024) Prevalence of Iron Overload in Patients with Chronic Kidney Disease on Peritoneal Dialysis: A Scoping Review. HealthScienceReports, 7, e2255. https://doi.org/10.1002/hsr2.2255
[12]
Nashwan, A.J., Yassin, M.A., Abd‐Alrazaq, A., Shuweihdi, F., Othman, M., Abdul Rahim, H.F., et al. (2022) Hepatic and Cardiac Iron Overload Quantified by Magnetic Resonance Imaging in Patients on Hemodialysis: A Systematic Review and Meta‐Analysis. HemodialysisInternational, 27, 3-11. https://doi.org/10.1111/hdi.13054
[13]
Holman, R., Olynyk, J.K., Kulkarni, H. and Ferrari, P. (2017) Characterization of Hepatic and Cardiac Iron Deposition during Standard Treatment of Anaemia in Haemodialysis. Nephrology, 22, 114-117. https://doi.org/10.1111/nep.12735
[14]
Roa, K.V. and Anderson, R. (1985) Hemosiderosis and Hemochromatosis in Renal Transplant Recipients. Clinical and Pathological Features, Diagnostic Correlation, Predisposing Factors and Treatment. American Journal of Nephrology, 5, 419-430.
[15]
Blunden, R.W., Lloyd, J.V., Rudzki, Z. and Kimber, R.J. (1981) Changes in Serum Ferritin Levels after Intravenous Iron. AnnalsofClinicalBiochemistry: InternationalJournalofLaboratoryMedicine, 18, 215-217. https://doi.org/10.1177/000456328101800405
[16]
Cecchin, E., De Marchi, S., Querin, F., Marin, M.G., Fiorentino, R. and Tesio, F. (1990) Efficacy of Hepatic Computed Tomography to Detect Iron Overload in Chronic Hemodialysis. KidneyInternational, 37, 943-950. https://doi.org/10.1038/ki.1990.69
[17]
Salomao, M.A. (2021) Pathology of Hepatic Iron Overload. ClinicalLiverDisease, 17, 232-237. https://doi.org/10.1002/cld.1051
[18]
Pietrangelo, A. (2010) Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment. Gastroenterology, 139, 393-408.e2. https://doi.org/10.1053/j.gastro.2010.06.013
[19]
Suprapti, E., Hadju, V., Ibrahim, E., Indriasari, R., Erika, K.A. and Balqis, B. (2025) Anemia: Etiology, Pathophysiology, Impact, and Prevention: A Review. IranianJournalofPublicHealth, 54, 509-520. https://doi.org/10.18502/ijph.v54i3.18244
[20]
Hashmi, M.F., Shaikh, H. and Rout, P. (2024) Anemia of Chronic Kidney Disease. StatPearls.
[21]
El-Reshaid, K., Johny, K.V., Hakim, A., Kamel, H., Sebeta, A., Hourani, H., et al. (2009) Erythropoietin Treatment in Haemodialysis Patients with Iron Overload. ActaHaematologica, 91, 130-135. https://doi.org/10.1159/000204318
[22]
Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., et al. (1998) The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin. NewEnglandJournalofMedicine, 339, 584-590. https://doi.org/10.1056/nejm199808273390903
[23]
Coyne, D.W., Kapoian, T., Suki, W., Singh, A.K., Moran, J.E., Dahl, N.V., et al. (2007) Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. JournaloftheAmericanSocietyofNephrology, 18, 975-984. https://doi.org/10.1681/asn.2006091034
[24]
Palmer, S.C., Navaneethan, S.D., Craig, J.C., Johnson, D.W., Tonelli, M., Garg, A.X., et al. (2010) Meta-Analysis: Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease. AnnalsofInternalMedicine, 153, 23-33. https://doi.org/10.7326/0003-4819-153-1-201007060-00252
[25]
Kotla, N.K., Dutta, P., Parimi, S. and Das, N.K. (2022) The Role of Ferritin in Health and Disease: Recent Advances and Understandings. Metabolites, 12, Article 609. https://doi.org/10.3390/metabo12070609
[26]
Lowe, D., Sanvictores, T., Zubair, M. and John, S. (2026) Serum Alkaline Phosphatase: Clinical and Laboratory Perspectives. StatPearls.
[27]
Olynyk, J.K. and Ramm, G.A. (2022) Hemochromatosis. NewEnglandJournalofMedicine, 387, 2159-2170. https://doi.org/10.1056/nejmra2119758